摘要
目的:高血压是导致阿尔茨海默氏病(AD)的危险因素,它通常可治愈,并为预防AD提供了可能。血管紧张素II(AngII)的升高是导致高血压的重要原因。血管紧张素Ⅱ对血管内皮功能及脑血流(CBF)有着不利影响,这可能会导致AD。因此,血管紧张素Ⅱ拮抗剂可以降低高血压患者患AD的危险。方法:我们研究了野生型(WT)C57bl/6j a和 AβPPswe/PS1ΔE9 (AβPP/PS1) 小鼠中2个月高压状态(通过渗透微泵输注AngII)对其血液收缩压(SBP)和 CBF的影响,并且之后用两种不同的抗高血压药物治疗,一种为依普罗沙坦(EM, 0.35mg/kg) ,另一种为二氢氯噻(HCT, 7.5mg/kg)。利用尾套体积描记法每月对收缩压进行两次监测,磁共振流动敏感交互式反转恢复灌注成像技术测量CBF。慢性血管紧张素Ⅱ灌注诱导的AβPP/PS和WT 1小鼠都表现为收缩压升高,在海马和丘脑CBF仅在AβPP/PS1小鼠有所降低。AβPP/PS1鼠WT鼠的另一个不同是不管在 高血压还是正常血压状态下,WT鼠的SBP要更高。除此之外,对AβPP/PS1小鼠来说,两种抗高血压药对降低AngII诱导的高血压使其恢复正常水平的效果并不明显,而对WT小鼠却十分有效。结论:转基因模型AD中,AngII诱导的SBP升高导致脑血流量异常,使对降压治疗响应减少。结果表明,在AD小鼠模型中,中年高血压患者和脑血流量减少的关系可以类比至人类AD患者身上。该小鼠模型可以用来研究寻找预防和治疗AD的方法。
关键词: 阿尔茨海默病、血管紧张素Ⅱ、血管紧张素Ⅱ受体阻断剂、脑血管循环、利尿剂、高血压。
Current Alzheimer Research
Title:Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Volume: 12 Issue: 10
Author(s): Maximilian Wiesmann, Carmen Capone, Valerio Zerbi, Laura Mellendijk, Arend Heerschap, Jurgen A.H.R. Claassen and Amanda J. Kiliaan
Affiliation:
关键词: 阿尔茨海默病、血管紧张素Ⅱ、血管紧张素Ⅱ受体阻断剂、脑血管循环、利尿剂、高血压。
摘要: Aims: Hypertension, a risk factor for Alzheimer’s disease (AD), is a treatable condition, which offers possibilities for prevention of AD. Elevated angiotensin II (AngII) is an important cause of essential hypertension. AngII has deleterious effects on endothelial function and cerebral blood flow (CBF), which may contribute to AD. AngII blocking agents can thus provide potential candidates to reduce AD risk factors in hypertensive patients. Methods: We studied the effect of 2 months induced hypertension (AngII-infusion via osmotic micropumps) on systolic blood pressure (SBP) and CBF in 10 months-old wild-type (WT) C57bl/6j and AβPPswe/PS1ΔE9 (AβPP/PS1) mice, and treatment with two different antihypertensives, 1) eprosartan mesylate (EM, 0.35mg/kg) or 2) hydrochlorotiazide (HCT, 7.5mg/kg), after 1 month of induced-hypertension. SBP was monitored twice each month via tail cuff plethysmography. CBF was measured with MR by flow-sensitive alternating inversion recovery. Results: Chronic AngII-infusion induced an increase in SBP in both AβPP/PS1 and WT mice accompanied by a decrease in hippocampal and thalamic CBF only in the AβPP/PS1 mice. An additional difference between the AβPP/PS1 mice and WT mice was that SBP was much higher in AβPP/PS1 mice in both hypertensive and normotensive conditions. Moreover, both antihypertensives were less effective in reducing AngII-induced hypertension to normal levels in AβPP/PS1 mice, while being effective in WT mice. Conclusions: It can be concluded that AngII-induced elevated SBP results in impaired CBF and a decreased response to blood pressure lowering treatment in a transgenic model of AD. Our findings suggest a relation between midlife hypertension and decreased CBF in an AD mouse model, similar to the relation which has been found in AD patients. This translational mouse model could be used to investigate possible prevention and treatment strategies for AD.
Export Options
About this article
Cite this article as:
Maximilian Wiesmann, Carmen Capone, Valerio Zerbi, Laura Mellendijk, Arend Heerschap, Jurgen A.H.R. Claassen and Amanda J. Kiliaan , Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027130135
DOI https://dx.doi.org/10.2174/1567205012666151027130135 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in <i>Helicobacter Pylori</i> Eradication
Anti-Infective Agents Micro-RNAs, Exercise and Cellular Plasticity in Humans: The Impact of Dietary Factors and Hypoxia
MicroRNA Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Mitochondria-Targeted Drugs
Current Molecular Pharmacology Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Clinical Application of PET Myocardial Perfusion Imaging
Current Medical Imaging Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry